Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 63
Filtrar
1.
Eur J Haematol ; 112(4): 530-537, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38031389

RESUMEN

OBJECTIVES: To compare the efficacy of venetoclax-azacitidine (VEN-AZA) with AZA in the real-life for patients with first relapsed or refractory acute myeloid leukaemia (R/R AML). METHODS: We retrospectively analysed R/R AML patients treated with VEN-AZA at the Institut Paoli Calmettes between September 2020 and February 2022. We compared them to a historical cohort of patients treated with AZA between 2010 and 2021. RESULTS: Thirty-five patients treated with VEN-AZA were compared with 140 patients treated with AZA. There were more favourable cytogenetics (25.7% vs. 8.6%; p = 0.01) and less FLT3-ITD mutated AML (8.8% vs. 25.5%; p = .049) in the VEN-AZA group. The overall 30-day mortality rate was 7.4% and the overall 90-day mortality was 20%, with no difference between the groups. The complete remission rate was 48.6% in the VEN-AZA group versus 15% (p < .0001). The composite complete response rate was 65.7% in the VEN-AZA group versus 23.6% (p < .0001). OS was 12.8 months in the VEN-AZA group versus 7.3 months (p = 0.059). Patients with primary refractory AML, poor-risk cytogenetics, prior hematopoietic stem-cell transplantation (HSCT) and FLT3-ITD mutated AML had lower response and survival rates. CONCLUSION: VEN-AZA was associated with a better response rate and a longer survival than AZA monotherapy in AML patients who relapsed after or were refractory to intensive chemotherapy.


Asunto(s)
Azacitidina , Compuestos Bicíclicos Heterocíclicos con Puentes , Leucemia Mieloide Aguda , Sulfonamidas , Humanos , Azacitidina/uso terapéutico , Terapia Recuperativa , Estudios Retrospectivos , Leucemia Mieloide Aguda/diagnóstico , Leucemia Mieloide Aguda/tratamiento farmacológico , Leucemia Mieloide Aguda/genética , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos
2.
Opt Express ; 30(22): 39374-39381, 2022 Oct 24.
Artículo en Inglés | MEDLINE | ID: mdl-36298891

RESUMEN

The split photodiode and the lateral effect photodiode are two popular detectors for measuring beam displacement. For small displacements of a Gaussian beam, which is the case of interest here, they are often seen as equivalent and used interchangeably, giving a signal proportional to the displacement. We show theoretically and experimentally that in the limit of low technical noise, where the signal to noise ratio is dominated by the shot noise of the light, the lateral effect photodiode produces a better signal to noise ratio than the split photodiode, owing to its optimum spatial detector response. This quantum advantage can be practically exploited in spite of the intrinsic thermal noise of the lateral effect photodiode.

3.
J Dairy Sci ; 104(3): 3327-3338, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33358814

RESUMEN

Dairy cows housed in tiestalls are restricted to one space; therefore, this space should be designed to accommodate all the activities cows need to perform. Lying is a very important behavior for dairy cows as well as a critical measure in the assessment of stall designs, to ensure that the cows' needs for resting space are met. The objective of this study was to determine if increasing tiestall width alters the lying behavior of lactating dairy cows. Two treatments were compared: the current recommendation (139 cm) and a double stall (284 cm). Sixteen cows were blocked by parity and lactation stage, then randomly allocated to a treatment and a stall within 1 of 2 rows in the research barn, for 6 wk. The average stall length was 188 cm. Leg-mounted accelerometers were used to record lying behaviors. Cows were video-recorded 24 h/wk using surveillance cameras positioned above the stalls. Video data from wk 1, 3, and 6 were extracted at a rate of 1 image/min and analyzed by a trained observer to assess the position and the location of the cow's body, head, and limbs during the lying hours. Lying behaviors and frequency of each position and location were analyzed in SAS (SAS Institute Inc., Cary, NC) using a mixed model in which treatment, block, and week were included as fixed factors, and cow and row as random factors. Multiple comparisons were adjusted using the Scheffé method. Results indicate that cows in double stalls fully extended their hindlimbs more often than single stall cows (21.7 vs. 7.6% of lying time). Cows in double stalls also intruded in the neighboring stalls with their hindlimbs less often (1.3 vs. 14.7% of lying time), instead positioning them inside their own stall more often (92.7 vs. 84.6% of lying time). Use of the second stall in the double stall group totaled 11.6, 5.1, 33.8, and 18.0% of lying time, respectively, for the head, front legs, hind legs, and body. Total lying time was not statistically different between double (716 min/d) and single stall (671 min/d) groups. Contacts with stall hardware during lying-down movements were also less frequent in double stalls (43.1 vs. 77.1% of lying events) compared with single stalls. These results suggest that dairy cows housed in double stalls modified their resting habits and used the extra space made available to them. Increasing stall width beyond the current recommendation is likely to benefit the cows by improving their ability to rest.


Asunto(s)
Industria Lechera , Lactancia , Animales , Conducta Animal , Bovinos , Femenino , Vivienda para Animales , Paridad , Embarazo
4.
J Dairy Sci ; 104(3): 3316-3326, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33358818

RESUMEN

Although most farms in Canada still use tiestall housing for dairy cows, little information is available pertaining to cow comfort and behavior in such systems. Tiestalls are often criticized as they offer a reduced dynamic space to cows, thereby restricting their ability to move. The object of this study was to see if increasing the length of the tie chain provides cows with improved movement opportunities and to measure its effect on cows' rising and lying movements and behaviors. Two treatments were tested: the current recommendation of 1.00 m (recommended) and a longer chain of 1.40 m (long). Twenty-four cows (12/treatment) were blocked by parity number and lactation stage, then randomly allocated to a treatment and a stall within one of 2 rows in the research barn for 10 wk. Leg-mounted accelerometers were used to record lying behaviors and moments of transition between lying and standing positions for all cows. Cows were video-recorded for 24 h/wk using cameras positioned above the stall. The videos were used to evaluate the cows' rising and lying-down movements on wk 1, 2, 3, 6, 8, and 10. Six rising and 6 lying-down motions per cow per week were assessed by a trained observer to detect the presence of abnormal behaviors. Differences between and within treatments over time were analyzed in SAS (SAS Institute Inc., Cary, NC) using a mixed model with treatment, week, and block as fixed effects and with row and cow as random effects. Data from wk 1-3 were grouped together as the short-term effects, and those from wk 8-10 as the long-term effects. Week 6 was used as the mid-term assessment for analysis. Multiple comparisons between terms were accounted for using a Scheffé adjustment. Results indicate that duration of intention movements (exploratory head movements made by cows before lying down) is shorter in cows with longer chains (13.6 ± 1.03 s vs. 16.8 ± 1.01 s). It was also significantly shorter in the long term compared with the short term for both treatments (13.3 ± 0.92 s vs. 16.9 ± 0.81 s). These results suggest that increasing the chain length improves the cows' ease of movement and transitions, although all cows became more at ease in their surroundings with time. It may provide evidence of a potential way to improve the dynamic space provided to cows in tiestall systems, using a simple, affordable modification.


Asunto(s)
Enfermedades de los Bovinos , Industria Lechera , Animales , Conducta Animal , Canadá , Bovinos , Femenino , Vivienda para Animales , Lactancia , Embarazo
5.
J Dairy Sci ; 104(3): 3751-3760, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33358785

RESUMEN

Given increased societal concern for the welfare of dairy cattle and the heightened concern of consumers about the ability of cows to fulfill their needs for rest and for movement, an understanding of the effect of stall-based housing systems on such needs becomes of prime scientific importance. In tie-stall systems, the ability of the cow to express her need for movement is largely affected by tethering; increasing chain length increased the cow's ease of movement in the space allowed to her. Regarding the ability of the cow to rest, the size of the stall bed (including its width) has been linked with measures of lying time. For the most part, current industry recommendations are not being followed on commercial farms, although improvements in terms of compliance seem to have been made in the last decade. Following the recommendations for chain length appears to aid in reducing the prevalence of injuries and may even aid in maintaining the cleanliness of the cows, although the few studies available are inconsistent. Wider stalls were associated with increased lying time and reduced prevalence of injuries, although in the latter case, data from different studies show inconsistent results. The link between stall width and common welfare outcome measures appears more clearly in tiestall systems, although improving the lateral space allowance for cows reduces collisions with equipment in freestall systems as well. Overall, the width of the stall and the length of the chain play roles in modulating the cows' ability to rest and to move comfortably in the confines of the stall, and should be carefully considered when designing stall-based housing systems that enhance the welfare of dairy cows.


Asunto(s)
Vivienda para Animales , Estudiantes , Animales , Bovinos , Industria Lechera , Granjas , Femenino , Humanos , Evaluación de Resultado en la Atención de Salud , Prevalencia
6.
Ann Hematol ; 99(4): 773-780, 2020 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-32088745

RESUMEN

Although complete remission (CR) is achieved in 50 to 70% of older fit patients with acute myeloid leukemia (AML), consolidation therapy in this age group remains challenging. In this retrospective study, we aimed to compare outcome in elderly patients treated with different post-remission modalities, including allogenic and autologous hematopoietic stem cell transplantation (HSCT), intensive chemotherapy, and standard-dose chemotherapy (repeated 1 + 5 regimen). We collected data of 441 patients ≥ 60 years in first CR from a single institution. Median age was 67 years. Sixty-one (14%) patients received allo-HSCT, 51 (12%) auto-HSCT, 70 (16%) intensive chemotherapy with intermediate- or high-dose cytarabine (I/HDAC), and 190 (43%) 1 + 5 regimen. Median follow-up was 6.5 years. In multivariate analysis, allo-HSCT, cytogenetics, and PS had a significant impact on OS and LFS. In spite of a more favorable-risk profile, the patients who received I/HDAC had no significantly better LFS as compared with patients treated with 1 + 5 (median LFS 8.8 months vs 10.6 months, p = 0.96). In transplanted patients, median LFS was 13.3 months for auto-HSCT and 25.8 months for allo-HSCT. Pre-transplant chemotherapy with I/HDAC had no effect on the outcome. Toxicity was significantly increased for both transplanted and non-transplanted patients treated with I/HDAC, with more units of blood and platelet transfusion and more time spent in hospitalization, but no higher non-relapse mortality. This study shows that post-remission chemotherapy intensification is not associated with significantly better outcome as compared with standard-dose chemotherapy in elderly patients for whom, overall results remain disappointing.


Asunto(s)
Quimioterapia de Consolidación , Leucemia Mieloide Aguda/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Aloinjertos , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Transfusión de Componentes Sanguíneos , Terapia Combinada , Citarabina/administración & dosificación , Citarabina/efectos adversos , Daunorrubicina/administración & dosificación , Daunorrubicina/efectos adversos , Supervivencia sin Enfermedad , Femenino , Estudios de Seguimiento , Trasplante de Células Madre Hematopoyéticas , Humanos , Estimación de Kaplan-Meier , Leucemia Mieloide Aguda/terapia , Masculino , Persona de Mediana Edad , Inducción de Remisión , Estudios Retrospectivos , Trasplante Autólogo , Resultado del Tratamiento
7.
HIV Med ; 20(1): 38-46, 2019 01.
Artículo en Inglés | MEDLINE | ID: mdl-30362279

RESUMEN

OBJECTIVES: In terms of HIV infection, western and central Africa is the second most affected region world-wide, and the gap between the regional figures for the testing and treatment cascade and the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets is particularly worrying. We assessed the prevalence of virological suppression in patients routinely treated in 19 hospitals in Cameroon. METHODS: A cross-sectional survey was performed in adult patients receiving antiretroviral therapy (ART) in the Centre and Littoral regions. The prevalences of virological suppression (<1000 HIV-1 RNA copies/mL) were compared among all 19 hospitals using the χ2 test. Potential individual and health care-related determinants of virological suppression were assessed using multivariate logistic regression models. RESULTS: A total of 1700 patients (74% women; median age 41 years; median time on ART 3.7 years) were included in the study. The prevalence of virological suppression was 82.4% overall (95% confidence interval 80.5-84.2%). It ranged from 57.1 to 97.4% according to the individual hospital (P < 0.001). After adjustment, virological suppression was associated with age, CD4 cell count at ART initiation, disclosure of HIV status to family members, interruption of ART for more than two consecutive days, and location of patient's residence and hospital (rural/urban). These factors did not explain the heterogeneity of virological suppression between the study hospitals (P < 0.001). CONCLUSIONS: The overall prevalence of virological suppression was reassuring. Nevertheless, the heterogeneity of virological suppression among hospitals highlights that, in addition to programme-level data, health facility-level data are crucial in order to tailor the national AIDS programme's interventions with a view to achieving the third UNAIDS 90 target.


Asunto(s)
Antirretrovirales/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , VIH-1/fisiología , Adulto , Antirretrovirales/farmacología , Recuento de Linfocito CD4 , Camerún/epidemiología , Estudios Transversales , Femenino , VIH-1/efectos de los fármacos , Humanos , Masculino , Cumplimiento de la Medicación , Persona de Mediana Edad , Prevalencia , ARN Viral/efectos de los fármacos , Población Rural , Encuestas y Cuestionarios , Carga Viral/efectos de los fármacos
8.
Intensive Care Med ; 44(11): 1777-1786, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-30343312

RESUMEN

PURPOSE: We describe the impact of a multifaceted program for decreasing ventilator-associated pneumonia (VAP) after implementing nine preventive measures, including selective oropharyngeal decontamination (SOD). METHODS: We compared VAP rates during an 8-month pre-intervention period, a 12-month intervention period, and an 11-month post-intervention period in a cohort of patients who received mechanical ventilation (MV) for > 48 h. The primary objective was to assess the effect on first VAP occurrence, using a Cox cause-specific proportional hazards model. Secondary objectives included the impact on emergence of antimicrobial resistance, antibiotic consumption, duration of MV, and ICU mortality. RESULTS: Pre-intervention, intervention and post-intervention VAP rates were 24.0, 11.0 and 3.9 VAP episodes per 1000 ventilation-days, respectively. VAP rates decreased by 56% [hazard ratio (HR) 0.44, 95% CI 0.29-0.65; P < 0.001] in the intervention and by 85% (HR 0.15, 95% CI 0.08-0.27; P < 0.001) in the post-intervention periods. During the intervention period, VAP rates decreased by 42% (HR 0.58, 95% CI 0.38-0.87; P < 0.001) after implementation of eight preventive measures without SOD, and by 70% after adding SOD (HR 0.30, 95% CI 0.13-0.72; P < 0.001) compared to the pre-intervention period. The incidence density of intrinsically resistant bacteria (to colistin or tobramycin) did not increase. We documented a significant reduction of days of therapy per 1000 patient-days of broad-spectrum antibiotic used to treat lower respiratory tract infection (P < 0.028), median duration of MV (from 7.1 to 6.4 days; P < 0.003) and ICU mortality (from 16.2 to 13.5%; P < 0.049) for patients ventilated > 48 h between the pre- and post-intervention periods. CONCLUSIONS: Our preventive program produced a sustained decrease in VAP incidence. SOD provides an additive value.


Asunto(s)
Cuidados Críticos , Descontaminación , Orofaringe , Neumonía Asociada al Ventilador/prevención & control , Anciano , Antibacterianos/uso terapéutico , Estudios de Cohortes , Estudios Controlados Antes y Después , Femenino , Humanos , Incidencia , Tiempo de Internación , Masculino , Persona de Mediana Edad , Neumonía Asociada al Ventilador/epidemiología , Modelos de Riesgos Proporcionales , Respiración Artificial
10.
AIDS Care ; 28(11): 1345-54, 2016 11.
Artículo en Inglés | MEDLINE | ID: mdl-27267205

RESUMEN

HAART has improved the well-being of many people living with HIV (PLWH). This study aimed at (i) comparing heterosexual practices between PLWH and the general population by gender, and (ii) identifying factors associated with sexual practices and at-risk behaviors in the two populations. Self-reported data were collected among PLWH attending hospitals (VESPA2 survey; n = 3022) and the general population (CSF survey; n = 10,280). Significant differences between the two samples were corrected for by implementing propensity score matching on both socio-demographic characteristics and sexual behavior in terms of number of partners. Men not reporting heterosexual intercourse were excluded. After matching, 61% of women (out of 707) and 68% of men (out of 709) were sexually active in both populations. PLWH practiced oral sex less than the general population and used condoms more consistently over the previous 12-month period, irrespective of having multiple sexual partners or not. For women living with HIV: those with several sexual partners and those consuming drugs over the previous 12 months were more likely to practice oral sex; those living in a couple for at least 6 years and migrants were less likely to practice anal intercourse. For men living with HIV: those reporting bisexual relationships and those with multiple sexual partners over the previous 12 months were more likely to practice anal heterosexual intercourse; migrants reported less oral sex, irrespective of HIV status. Error term correlations showed that anal intercourse was not linked to condom use for women or men from either population. Our results show that PLWH had a lower rate of heterosexual practices compared with the general population, and used condoms more often, irrespective of the number of sexual partners and strong cultural background (e.g., for Sub-Saharan African women). Further preventive information needs to be disseminated on the risk of infection transmission through heterosexual anal intercourse.


Asunto(s)
Condones/estadística & datos numéricos , Infecciones por VIH , Heterosexualidad/estadística & datos numéricos , Adolescente , Adulto , Bisexualidad , Estudios de Casos y Controles , Femenino , Francia , Infecciones por VIH/prevención & control , Infecciones por VIH/psicología , Heterosexualidad/etnología , Humanos , Masculino , Persona de Mediana Edad , Asunción de Riesgos , Factores Sexuales , Parejas Sexuales , Encuestas y Cuestionarios , Migrantes/estadística & datos numéricos , Adulto Joven
12.
Orthop Traumatol Surg Res ; 101(1 Suppl): S101-8, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25596987

RESUMEN

Viscosupplementation by hyaluronic acid (HA) injections is frequently used for local treatment of osteoarthritis (OA), due to ease of use and good tolerance. A profusion of linear or reticulated HA derivates are marketed, with varied characters and levels of evidence. Viscosupplementation has demonstrated moderate but significant efficacy (20%) versus placebo in terms of pain and function, with a high rate of responders (60-70%) in knee osteoarthritis. It allows reduced administration of opioid analgesics and NSAIDs, with improved risk/benefit ratio, and may delay joint replacement. Cartilage protection remains to be proven. Clinical efficacy shows 1-4 weeks' later onset than corticosteroids, but is maintained for 6 or even 12 months. Systematic association of corticosteroid and HA injection is not justified, and an interval has to be left before undertaking arthroplasty. Intra-articular injection of HA requires a skilled specialist, and may be difficult in a non-swollen joint; some tips and tricks may be helpful. In other joints than the knee, radiologic or ultrasound guidance is recommended. The efficacy of viscosupplementation is a matter of ongoing debate, after discordant findings in some meta-analyses. Some poor results may be due to inappropriate use of HA injections, poorly adapted to the patient's OA phenotype. Viscosupplementation is a treatment for chronic moderate symptomatic OA, and not for flares with joint swelling. Application in sport-related chondropathy has yet to be properly assessed. The optimal response profile remains to be determined. The ideal indication in the knee seems to be moderate femorotibial OA without swelling. Results have been generally disappointing in hip osteoarthritis but promising in OA of the ankle and shoulder (with and without rotator cuff tear). Further studies are needed to determine response profile and optimal treatment schedule, according to the joint.


Asunto(s)
Ácido Hialurónico/administración & dosificación , Ácido Hialurónico/uso terapéutico , Osteoartritis/tratamiento farmacológico , Viscosuplementación/métodos , Articulación del Tobillo/fisiopatología , Humanos , Ácido Hialurónico/efectos adversos , Inyecciones Intraarticulares , Osteoartritis/fisiopatología , Osteoartritis de la Cadera/tratamiento farmacológico , Osteoartritis de la Cadera/fisiopatología , Osteoartritis de la Rodilla/tratamiento farmacológico , Osteoartritis de la Rodilla/fisiopatología , Articulación del Hombro/fisiopatología , Resultado del Tratamiento
14.
J Gynecol Obstet Biol Reprod (Paris) ; 43(7): 534-48, 2014 Sep.
Artículo en Francés | MEDLINE | ID: mdl-24947850

RESUMEN

With effective antiretroviral therapy, the risk of mother to child transmission (MTCT) is now under 1%. The 2013 French guidelines emphasize early antiretroviral lifelong antiretroviral therapy. Thus, the current trend for women living with HIV is to take antiretroviral therapy before, during and after their pregnancies. A major issue today is the choice of antiretroviral drugs, to maximize the benefits and minimize the risks of fetal exposure. This requires interdisciplinary care. The use of effective therapies permits gradual but profound changes in obstetric practice. When maternal plasma viral load is controlled (<50 copies/ml), obstetrical care can be more similar to standards in HIV-negative women. Prophylactic cesarean section is recommended when the viral load in late pregnancy is above 400 copies/mL. Intravenous zidovudine during labor is recommended only if the last maternal viral load is>400 copies/mL or in case of complications such as preterm delivery, bleeding or chorio-amnionitis during labor. In case of premature rupture of membranes before 34 weeks, a multidisciplinary decision should be made, based on gestational age and control of maternal viral load; if the woman is under antiretroviral therapy and especially if her viral load is undetectable, steroids and antibiotics should be offered and pregnancy can be continued except in case of signs or symptoms of chorio-amnionitis. Breastfeeding is not recommended in women living with HIV in France, as in industrialized countries. Prophylaxis in the newborn is usually zidovudine for 1 month. In case of significant exposure to HIV perinatally, in particular when, maternal viral load is>1000 copies/mL, prophylactic combination therapy is recommended. Monitoring of the child is necessary to determine whether or not it is free of HIV infection and to monitor possible adverse effects of perinatal exposure to antiretroviral drugs.


Asunto(s)
Antirretrovirales/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Complicaciones Infecciosas del Embarazo/tratamiento farmacológico , Femenino , Infecciones por VIH/complicaciones , Humanos , Embarazo
16.
Leukemia ; 25(7): 1147-52, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21494260

RESUMEN

The impact of ten-eleven-translocation 2 (TET2) mutations on response to azacitidine (AZA) in MDS has not been reported. We sequenced the TET2 gene in 86 MDS and acute myeloid leukemia (AML) with 20-30% blasts treated by AZA, that is disease categories wherein this drug is approved by Food and Drug Administration (FDA). Thirteen patients (15%) carried TET2 mutations. Patients with mutated and wild-type (WT) TET2 had mostly comparable pretreatment characteristics, except for lower hemoglobin, better cytogenetic risk and longer MDS duration before AZA in TET2 mutated patients (P=0.03, P=0.047 and P=0.048, respectively). The response rate (including hematological improvement) was 82% in MUT versus 45% in WT patients (P=0.007). Mutated TET2 (P=0.04) and favorable cytogenetic risk (intermediate risk: P=0.04, poor risk: P=0.048 compared with good risk) independently predicted a higher response rate. Response duration and overall survival were, however, comparable in the MUT and WT groups. In higher risk MDS and AML with low blast count, TET2 status may be a genetic predictor of response to AZA, independently of karyotype.


Asunto(s)
Antimetabolitos Antineoplásicos/uso terapéutico , Azacitidina/uso terapéutico , Proteínas de Unión al ADN/genética , Leucemia Mieloide Aguda/genética , Mutación , Síndromes Mielodisplásicos/genética , Proteínas de Neoplasias/genética , Proteínas Proto-Oncogénicas/genética , Anciano , Anciano de 80 o más Años , Metilación de ADN/efectos de los fármacos , ADN de Neoplasias/genética , Proteínas de Unión al ADN/fisiología , Dioxigenasas , Supervivencia sin Enfermedad , Femenino , Hemoglobinas/análisis , Humanos , Estimación de Kaplan-Meier , Cariotipificación , Leucemia Mieloide Aguda/sangre , Leucemia Mieloide Aguda/tratamiento farmacológico , Leucemia Mieloide Aguda/patología , Recuento de Leucocitos , Masculino , Persona de Mediana Edad , Síndromes Mielodisplásicos/sangre , Síndromes Mielodisplásicos/tratamiento farmacológico , Síndromes Mielodisplásicos/patología , Proteínas de Neoplasias/fisiología , Proteínas Proto-Oncogénicas/fisiología , Análisis de Secuencia de ADN , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...